Macimorelin

Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) [1][2][3].

Product Specifications

CAS Number

[381231-18-1]

Product Name Alternative

EP-1572; AEZS-130

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

GHSR

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/macimorelin.html

Solubility

10 mM in DMSO

Smiles

O=CN[C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](NC(C(C)(N)C)=O)CC3=CNC4=CC=CC=C34)=O

Molecular Formula

C26H30N6O3

Molecular Weight

474.55

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103 (8) :3083-3093. |[2]An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28 (9) :3100-3112. |[3]Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34: